Categories: News

CLO Launches Marvelous Designer for Linux, Expanding Support for Professional Pipelines

NEW YORK, Sept. 25, 2025 /PRNewswire/ — CLO Virtual Fashion, a global leader in digital garment simulation and the creator of Marvelous Designer, today announced the release of Marvelous Designer for Linux, with support for Rocky Linux 9, Red Hat Enterprise Linux 9, and equivalent distributions.

- Advertisement -

Designed with an emphasis on stability and simulation accuracy, the Linux release for Marvelous Designer delivers a smooth user experience and seamless integration into professional 3D workflows. It also includes a Python API, enabling users to write and run scripts directly within Marvelous Designer, batch import and export files, adjust simulation parameters, and more.

- Advertisement -

“We’re excited to release Marvelous Designer for Linux to support many of our large VFX and game studio clients with complex pipelines primarily operating in Linux environments.” said Sean Jeon, CTO at CLO Virtual Fashion. “With a native Linux version, Marvelous Designer can now connect more naturally with existing Linux-based creation tools, opening up broader possibilities for automation across the production process.”

- Advertisement -

A free trial of Marvelous Designer for Linux, complete with all of the features of the standard release, is available here https://www.marvelousdesigner.com/pricing/trial/form

- Advertisement -

For more information, including full technical specifications and licensing options, visit the official Marvelous Designer website or email sales@marvelousdesigner.com.

- Advertisement -

About CLO Virtual Fashion:

- Advertisement -

CLO Virtual Fashion is the creator of Marvelous Designer, the Academy Award-winning 3D garment simulation software used and trusted by animators, game development studios, and VFX artists. With over two decades of research and development in accurate garment simulation, CLO Virtual Fashion’s mission is to empower users at every step of the garment journey. In addition to 3D garment design software, CLO Virtual Fashion’s products include CLO 3D (a leading 3D fashion design software),  CLO-SET (a digital collaboration platform), CONNECT (a digital fashion hub and marketplace), and consumer-facing solutions such as e-commerce virtual fittings. CLO’s interconnected and ever-growing product ecosystem is built to power the future of everything related to garments.

- Advertisement -

Video – https://www.youtube.com/watch?v=ImTbgQFxEdQ
Photo – https://mma.prnewswire.com/media/2782509/image_5025469_69398949.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/clo-launches-marvelous-designer-for-linux-expanding-support-for-professional-pipelines-302567712.html

- Advertisement -

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

6 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

6 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

6 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

6 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

6 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

6 hours ago